【佳学基因检测】杂合性分析丢失：在实践和概念上都有缺陷？

肿瘤基因检测回扣机会

参加学术会议时成人肿瘤与儿童肿瘤基因检测序列的异同点《肿瘤治疗效果与基因检测结果的相关性》《Genes Chromosomes Cancer》在. 2002 Aug;34(4):349-53.发表了一篇题目为《杂合性分析丢失：在实践和概念上都有缺陷？》肿瘤靶向药物治疗基因检测临床研究文章。该研究由Ian P M Tomlinson, Maryou B K Lambros, Rebecca R Roylance等完成。促进了肿瘤的精准治疗与个性化用药的发展，进一步强调了基因信息检测与分析的重要性。

肿瘤靶向药物及精准治疗临床研究内容关键词：

肿瘤靶向治疗基因检测临床应用结果

Knudson“两次打击”假说为旨在通过绘制等位基因丢失（杂合性丢失，LOH）区域来识别肿瘤抑制基因的研究提供了基本原理。尽管几乎在所有类型的肿瘤中都发现了 LOH，但很少有这样的项目能够成功地识别出它们的肿瘤抑制靶点。这种失败的主要解释可能是研究人员通常过于轻信两次打击假设，并且过于愿意忽略诸如肿瘤内异质性、正常细胞污染、核型复杂性、纯合缺失、基因剂量变化等因素和聚合酶链反应伪影。基因解码基因检测建议尽量减少这些问题的基因解码基因检测的研究方法。不幸的是，不能保证现有的或更新的基因解码基因检测的研究方法，如基因组微阵列和原位单核苷酸多态性分析，将解决 LOH 分析的困难。 LOH 研究的未来前景一如既往地不确定。

肿瘤发生与复发转移国际数据库描述：

The Knudson "two-hit" hypothesis has provided the rationale for studies that aim to identify tumor-suppressor genes by mapping regions of allelic loss (loss of heterozygosity, LOH). Although LOH has been found in practically all types of tumors, very few such projects have been successful in identifying their tumor-suppressor targets. The prime explanation for this failure is probably that researchers have, in general, been too credulous about the two-hit hypothesis, and too willing to ignore factors such as intratumor heterogeneity, contamination by normal cells, karyotypic complexity, homozygous deletions, gene dosage changes, and polymerase chain reaction artifacts. We suggest ways of minimizing these problems. Unfortunately, there is no guarantee that existing or newer methods, such as genomic microarrays and in situ single-nucleotide polymorphism analysis, will solve the difficulties of LOH analysis. The future prospects for LOH studies are, as ever, uncertain.